MCID: ACT008
MIFTS: 54

Actinic Keratosis

Categories: Skin diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Actinic Keratosis

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 76 55 15 73
Senile Hyperkeratosis 12
Seborrheic Keratosis 73
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 44
Solar Keratosis 12

Classifications:



Summaries for Actinic Keratosis

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to bowen's disease and squamous cell carcinoma. An important gene associated with Actinic Keratosis is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Mitotic G1-G1/S phases and MicroRNAs in cancer. The drugs Picato gel and Aminolevulinic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are growth/size/body region and behavior/neurological

Wikipedia : 76 Actinic keratosis (AK) is a pre-cancerous patch of thick, scaly, or crusty skin. These growths are more... more...

Related Diseases for Actinic Keratosis

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 bowen's disease 31.5 KRT17 PCNA
2 squamous cell carcinoma 31.1 CDKN2A PTGS2 TP53 TP63
3 keratoacanthoma 30.5 FLG KRT17 TP53
4 basal cell carcinoma 29.7 KRT17 KRT20 MC1R TP53 TP63
5 papilloma 28.4 CDKN2A FLG KRT20 PCNA TP53 TP63
6 keratosis 11.7
7 actinic cheilitis 11.2
8 brain stem astrocytic neoplasm 10.9 CDKN2A TP53
9 protoplasmic astrocytoma 10.9 PTGS2 TP53
10 vulvar intraepithelial neoplasia 10.9 MMP2 TP53
11 keratinizing squamous cell carcinoma 10.9 CDKN2A TP53
12 spitz nevus 10.9 CDKN2A TP53
13 bladder carcinoma in situ 10.8 CDKN2A TP53
14 bartholin's gland benign neoplasm 10.8 CDKN2A TP53
15 vulva squamous cell carcinoma 10.8 CDKN2A TP53
16 multicentric osteolysis, nodulosis, and arthropathy 10.8 MMP14 MMP2
17 thyroid lymphoma 10.8 CDKN2A TP53
18 winchester syndrome 10.8 MMP14 MMP2
19 nasal cavity adenocarcinoma 10.8 CDKN2A TP53
20 bizarre leiomyoma 10.8 CDKN2A PCNA
21 bone squamous cell carcinoma 10.8 CDKN2A TP53
22 bladder papillary transitional cell neoplasm 10.8 KRT20 TP53
23 urinary tract papillary transitional cell benign neoplasm 10.7 KRT20 TP53
24 eccrine sweat gland neoplasm 10.7 KRT20 TP53
25 scrotal carcinoma 10.7 CDKN2A TP53
26 anal squamous cell carcinoma 10.7 CDKN2A TP53
27 mucinous bronchioloalveolar adenocarcinoma 10.7 CDKN2A KRT20
28 balanitis xerotica obliterans 10.7 CDKN2A PTGS2
29 vulval paget's disease 10.7 CDKN2A KRT20
30 gastric adenosquamous carcinoma 10.7 CDKN2A TP53
31 papillary serous adenocarcinoma 10.7 KRT20 TP53
32 anogenital venereal wart 10.7 CDKN2A TP53
33 megaesophagus 10.6 CDKN2A TP53
34 barrett's adenocarcinoma 10.6 CDKN2A PTGS2 TP53
35 tongue cancer 10.6 CDKN2A MMP2 TP53
36 gastrointestinal system benign neoplasm 10.6 CDKN2A PTGS2 TP53
37 bladder squamous cell carcinoma 10.6 CDKN2A PTGS2 TP53
38 female reproductive organ cancer 10.6 CDKN2A MMP2 TP53
39 juvenile pilocytic astrocytoma 10.6 CDKN2A TNC TP53
40 respiratory system cancer 10.6 CDKN2A MMP2 TP53
41 testicular torsion 10.6 PCNA TP53
42 vulva adenocarcinoma 10.6 CDKN2A KRT20
43 tongue squamous cell carcinoma 10.6 CDKN2A MMP2 TP53
44 mature teratoma 10.6 PCNA TP53
45 malignant syringoma 10.6 KRT17 KRT20
46 oral leukoplakia 10.6 CDKN2A PCNA TP53
47 suppressor of tumorigenicity 3 10.6 CDKN2A PCNA TP53
48 basal cell carcinoma, infundibulocystic 10.6 KRT17 KRT20
49 larynx cancer 10.6 CDKN2A MMP2 TP53
50 ameloblastic carcinoma 10.6 CDKN2A TP63

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

MGI Mouse Phenotypes related to Actinic Keratosis:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.24 CDKN2A KRT17 LUM MC1R MCM2 MMP14
2 behavior/neurological MP:0005386 10.2 CDKN2A LUM MC1R MCM2 MMP14 PTGS2
3 cellular MP:0005384 10.19 CDKN2A KRT17 LUM MC1R MCM2 MMP14
4 immune system MP:0005387 10.16 CDKN2A LUM MC1R MCM2 MMP14 MMP2
5 hematopoietic system MP:0005397 10.13 CDKN2A LUM MC1R MCM2 MMP14 MMP2
6 digestive/alimentary MP:0005381 10.11 CDKN2A KRT17 LUM MCM2 MMP14 PTGS2
7 integument MP:0010771 10.09 KRT17 LUM MC1R MCM2 MMP14 PTGS2
8 muscle MP:0005369 10.01 CDKN2A LUM MCM2 MMP14 MMP2 PTGS2
9 craniofacial MP:0005382 10 TP63 KRT17 MC1R MMP14 MMP2 TP53
10 no phenotypic analysis MP:0003012 9.97 CDKN2A KRT17 MC1R MMP14 PCNA PTGS2
11 neoplasm MP:0002006 9.91 PTGS2 TP53 TP63 CDKN2A MC1R MCM2
12 normal MP:0002873 9.8 MCM2 MMP14 MMP2 PTGS2 TNC TP53
13 pigmentation MP:0001186 9.55 CDKN2A KRT17 MC1R MCM2 TP53
14 respiratory system MP:0005388 9.5 PTGS2 TP53 TP63 CDKN2A MCM2 MMP14
15 vision/eye MP:0005391 9.17 CDKN2A LUM MMP14 MMP2 PTGS2 TP53

Drugs & Therapeutics for Actinic Keratosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Picato gel 18 INGENOL MEBUTATE LEO Pharma January 2012

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 51-21-8 3385
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-72-7 338
6
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 15307-86-5 3033
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
9
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
10
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
11
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
12
Petrolatum Approved, Investigational Phase 4,Phase 2,Early Phase 1,Not Applicable 8009-03-8
13
Alginic acid Approved, Investigational Phase 4 9005-32-7
14
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
15
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
16
Menthol Approved Phase 4 2216-51-5 16666
17
Mycophenolic acid Approved Phase 4 24280-93-1 446541
18
Azathioprine Approved Phase 4 446-86-6 2265
19
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
21
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
22
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
23
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
24 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamins Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Keratolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Radiation-Protective Agents Phase 4,Phase 2
39 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1,Not Applicable
41 Clofibric Acid Phase 4 882-09-7
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Retinol palmitate Phase 4,Phase 3,Phase 2
44 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Emollients Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
47 Viscosupplements Phase 4
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Ergocalciferols Phase 4,Phase 1
50 Hypolipidemic Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
6 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
7 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
8 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
9 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
10 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
11 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
12 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
13 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
14 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
15 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
16 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
17 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
18 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine
19 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
20 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
21 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
22 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
23 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
24 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
25 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
26 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
27 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
28 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
29 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Recruiting NCT02866695 Phase 4 ingenol mebutate gel 0.015%
30 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Recruiting NCT03487588 Phase 4 A-101 Topical Solution
31 Treatment of Photodamaged Skin of the décolleté Recruiting NCT03573076 Phase 4
32 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
33 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
34 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
35 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
36 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
37 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
38 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
39 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
40 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
41 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
42 Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses Unknown status NCT02473848 Phase 3 ingenol mebutate 500 ucg
43 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
44 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
45 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
46 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
47 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
48 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
49 Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Completed NCT02289768 Phase 3 5-fluorouracil/salicylic acid;Vehicle
50 A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed NCT00916006 Phase 3 PEP005 Gel;Vehicle gel

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

MalaCards organs/tissues related to Actinic Keratosis:

41
Skin, Testes, Kidney, T Cells, Neutrophil, Liver, Bone

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 598)
# Title Authors Year
1
Efficacy Endpoints in Clinical Trials in Actinic Keratosis. ( 29916197 )
2018
2
Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. ( 29779986 )
2018
3
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. ( 29620004 )
2018
4
Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months? ( 29667728 )
2018
5
Reflectance confocal microscopy: a crucial role for actinic keratosis treatment monitoring. ( 29846971 )
2018
6
Successful Treatment of Actinic Keratosis with Kanuka Honey. ( 29955399 )
2018
7
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
8
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. ( 29920789 )
2018
9
MART-1-Labeled Melanocyte Density and Distribution in Actinic Keratosis and Squamous Cell Cancer in situ: Pagetoid Melanocytes are a Potential Source of Misdiagnosis as Melanoma in Situ. ( 29943494 )
2018
10
Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS. ( 29665991 )
2018
11
Treatment of Grade II and III Actinic Keratosis Lesions with a Film-Forming Medical Device Containing Sunscreen/Piroxicam 0.8% and a Retinoic Acid/Glycolic Gel: A Pilot Trial. ( 29855896 )
2018
12
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
13
Photodynamic therapy with the use of superluminescent diodes (sLED) in the treatment of actinic keratosis. ( 29684690 )
2018
14
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
15
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
16
Energy-based devices for actinic keratosis field therapy. ( 29894524 )
2018
17
Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance. ( 29797670 )
2018
18
Swiss (German) Version of the Actinic Keratosis Quality of Life questionnaire. ( 29669340 )
2018
19
Validity and Reliability of the Dutch Adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). ( 29909413 )
2018
20
Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series. ( 29322431 )
2018
21
Treatment of Actinic Keratosis with Photodynamic Therapy Using Red or Green Light: A Comparative Study. ( 29963684 )
2018
22
Field-change actinic keratosis and immunosuppression: therapeutic options. ( 29668097 )
2018
23
Effectiveness and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of actinic keratosis and skin field cancerisation of the forearms: a randomized controlled trial. ( 29862491 )
2018
24
Detection of human papillomavirus in actinic keratosis. ( 29383738 )
2018
25
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. ( 29442526 )
2018
26
Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. ( 29316678 )
2018
27
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in San Gallicano Institute of Rome and a review of literature. ( 29368865 )
2018
28
Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. ( 29356164 )
2018
29
Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index. ( 29791916 )
2018
30
Correlations between histopathologic and dermoscopic findings in Korean actinic keratosis. ( 29676831 )
2018
31
Evaluation of T lymphocyte subpopulations in Actinic Keratosis, In Situ and Invasive Squamous Cell Carcinoma of the Skin. ( 29419888 )
2018
32
Self-expressed patient preferences for the treatment of actinic keratosis: results from a non-interventional study based on a real-life setting in Spain. ( 29402758 )
2018
33
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients - a randomized intra-individual controlled trial. ( 28796885 )
2017
34
Prevalence of actinic keratosis in a French cohort of elderly people: the PROOF study. ( 28906092 )
2017
35
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not "high risk": Diagnosis, management, and clinical outcomes in a series of 115 cases. ( 27889291 )
2017
36
A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. ( 28078678 )
2017
37
In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire. ( 28776637 )
2017
38
Dermatoscopic Patterns of Nonfacial Actinic Keratosis: Characterization of Pigmented and Nonpigmented Lesions. ( 28538027 )
2017
39
Field treatment of actinic keratosis on the scalp. ( 28581227 )
2017
40
Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. ( 29311040 )
2017
41
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas. ( 28267402 )
2017
42
Filaggrin loss-of-function mutations, atopic dermatitis and risk of actinic keratosis: results from two cross-sectional studies. ( 28213896 )
2017
43
Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. ( 28628678 )
2017
44
A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. ( 28805092 )
2017
45
Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial. ( 29399263 )
2017
46
Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015. ( 29344318 )
2017
47
Phasor-FLIM as a Screening Tool for the Differential Diagnosis of Actinic Keratosis, Bowen's Disease, and Basal Cell Carcinoma. ( 28661125 )
2017
48
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. ( 27785771 )
2017
49
Photodynamic therapy for actinic keratosis: Is the European consensus protocol for daylight PDT superior to conventional protocol for Aktilite CL 128 PDT? ( 28756154 )
2017
50
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017

Variations for Actinic Keratosis

Cosmic variations for Actinic Keratosis:

9
(show top 50) (show all 360)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM11183 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.799C>T p.R267W 17:7673821-7673821 3
2 COSM10705 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 3
3 COSM43753 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 3
4 COSM44135 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.724T>G p.C242G 17:7674239-7674239 3
5 COSM44218 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.536A>C p.H179P 17:7675076-7675076 3
6 COSM10863 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 17:7673787-7673787 3
7 COSM10889 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 3
8 COSM44495 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.559+2T>A p.? 17:7675051-7675051 3
9 COSM10726 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 3
10 COSM44523 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.863A>G p.N288S 17:7673757-7673757 3
11 COSM10659 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 3
12 COSM44544 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.766A>G p.T256A 17:7674197-7674197 3
13 COSM10662 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 3
14 COSM11066 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 3
15 COSM6903923 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.356C>T p.A119V 17:7676013-7676013 3
16 COSM10731 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.707A>G p.Y236C 17:7674256-7674256 3
17 COSM43952 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.710T>A p.M237K 17:7674253-7674253 3
18 COSM44023 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.560G>A p.G187D 17:7674971-7674971 3
19 COSM44151 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.535C>A p.H179N 17:7675077-7675077 3
20 COSM43544 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 3
21 COSM10812 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.722C>T p.S241F 17:7674241-7674241 3
22 COSM10648 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 3
23 COSM44393 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.821T>C p.V274A 17:7673799-7673799 3
24 COSM11451 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.672G>T p.E224D 17:7674859-7674859 3
25 COSM45765 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 17:7673541-7673541 3
26 COSM10654 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 3
27 COSM10725 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 3
28 COSM45114 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 3
29 COSM43995 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.740A>T p.N247I 17:7674223-7674223 3
30 COSM6970765 PTPRD skin,scalp,carcinoma,squamous cell carcinoma c.2471C>T p.P824L 9:8486346-8486346 3
31 COSM163485 PIK3CA skin,scalp,carcinoma,squamous cell carcinoma c.311C>T p.P104L 3:179199136-179199136 3
32 COSM6903911 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.332T>A p.M111K 1:114709687-114709687 3
33 COSM573 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.38G>A p.G13D 1:114716123-114716123 3
34 COSM6903859 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.4358G>A p.G1453D 1:119925458-119925458 3
35 COSM6903876 NOTCH2 skin,lower leg,carcinoma,squamous cell carcinoma c.5449G>A p.D1817N 1:119920259-119920259 3
36 COSM6903874 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.5164A>G p.S1722G 1:119922285-119922285 3
37 COSM6903856 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.4006G>A p.G1336R 1:119925810-119925810 3
38 COSM6903890 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.5930G>A p.G1977E 1:119917762-119917762 3
39 COSM6903983 NOTCH2 skin,lower leg,carcinoma,squamous cell carcinoma c.3052A>G p.T1018A 1:119940686-119940686 3
40 COSM6903862 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.4509C>A p.C1503* 1:119925307-119925307 3
41 COSM6903883 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.5653G>A p.A1885T 1:119919440-119919440 3
42 COSM6903843 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.2891G>A p.C964Y 1:119941616-119941616 3
43 COSM6903868 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.4860-1G>A p.? 1:119922779-119922779 3
44 COSM6903878 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.5480A>T p.D1827V 1:119919613-119919613 3
45 COSM6903881 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.5630G>A p.G1877D 1:119919463-119919463 3
46 COSM6903864 NOTCH2 skin,lower leg,carcinoma,squamous cell carcinoma c.4570A>G p.S1524G 1:119923926-119923926 3
47 COSM6903831 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.1738C>T p.H580Y 1:119963751-119963751 3
48 COSM6903826 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.1319T>G p.F440C 1:119967567-119967567 3
49 COSM1667036 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.337C>T p.R113* 1:120005407-120005407 3
50 COSM6903863 NOTCH2 skin,scalp,carcinoma,squamous cell carcinoma c.4510A>G p.K1504E 1:119925306-119925306 3

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

GO Terms for Actinic Keratosis

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.96 PCNA TP53
2 extracellular matrix GO:0031012 8.92 LUM MMP14 MMP2 TNC

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.72 CDKN2A KRT20 MCM2 TP53 TP63
2 response to oxidative stress GO:0006979 9.65 MMP14 PCNA PTGS2
3 response to organic cyclic compound GO:0014070 9.63 LUM MMP14 PTGS2
4 cornification GO:0070268 9.54 FLG KRT17 KRT20
5 response to X-ray GO:0010165 9.51 TP53 TP63
6 establishment of skin barrier GO:0061436 9.49 FLG TP63
7 intermediate filament organization GO:0045109 9.43 KRT17 KRT20
8 epidermis development GO:0008544 9.43 FLG KRT17 TP63
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.4 TP53 TP63
10 replicative senescence GO:0090399 9.16 CDKN2A TP53
11 mitotic G1 DNA damage checkpoint GO:0031571 8.96 TP53 TP63
12 cellular response to UV GO:0034644 8.92 PCNA PTGS2 TP53 TP63

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.5 CDKN2A FLG KRT17 KRT20 LUM MC1R
2 enzyme binding GO:0019899 9.46 MCM2 PCNA PTGS2 TP53
3 damaged DNA binding GO:0003684 9.13 PCNA TP53 TP63

Sources for Actinic Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....